Cargando…

Analysis of Local Recurrence Risk in Ductal Carcinoma In Situ and External Validation of the Memorial Sloan Kettering Cancer Center Nomogram

SIMPLE SUMMARY: Adjuvant treatments after breast-conserving surgery (BCS) in ductal carcinoma in situ (DCIS) have shown to reduce the risk of ipsilateral breast tumor relapse (IBTR), but its effect on overall survival remains controversial. Due to this argument, some nomograms tried to select the pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Oses, Gabriela, Mension, Eduard, Pumarola, Claudia, Castillo, Helena, Francesc, León, Torras, Inés, Cebrecos, Isaac, Caparrós, Xavier, Ganau, Sergi, Ubeda, Belén, Bargallo, Xavier, González, Blanca, Sanfeliu, Esther, Vidal-Sicart, Sergi, Moreno, Reinaldo, Muñoz, Montserrat, Santamaría, Gorane, Mollà, Meritxell
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136555/
https://www.ncbi.nlm.nih.gov/pubmed/37190320
http://dx.doi.org/10.3390/cancers15082392
_version_ 1785032246957178880
author Oses, Gabriela
Mension, Eduard
Pumarola, Claudia
Castillo, Helena
Francesc, León
Torras, Inés
Cebrecos, Isaac
Caparrós, Xavier
Ganau, Sergi
Ubeda, Belén
Bargallo, Xavier
González, Blanca
Sanfeliu, Esther
Vidal-Sicart, Sergi
Moreno, Reinaldo
Muñoz, Montserrat
Santamaría, Gorane
Mollà, Meritxell
author_facet Oses, Gabriela
Mension, Eduard
Pumarola, Claudia
Castillo, Helena
Francesc, León
Torras, Inés
Cebrecos, Isaac
Caparrós, Xavier
Ganau, Sergi
Ubeda, Belén
Bargallo, Xavier
González, Blanca
Sanfeliu, Esther
Vidal-Sicart, Sergi
Moreno, Reinaldo
Muñoz, Montserrat
Santamaría, Gorane
Mollà, Meritxell
author_sort Oses, Gabriela
collection PubMed
description SIMPLE SUMMARY: Adjuvant treatments after breast-conserving surgery (BCS) in ductal carcinoma in situ (DCIS) have shown to reduce the risk of ipsilateral breast tumor relapse (IBTR), but its effect on overall survival remains controversial. Due to this argument, some nomograms tried to select the patients who may benefit the most to these not free of side-effects adjuvant treatments. In this study, an external validation of the Memorial Sloan Kettering Cancer Center (MSKCC) nomogram was performed not reaching statistical significance in a Spanish cohort of patients. Nonetheless, the expression of estrogen receptors, not included in the MSKCC nomogram, showed potential prediction power for IBTR in the studied population and may be considered in future nomograms. ABSTRACT: Background: Adjuvant radiotherapy and hormonotherapy after breast-conserving surgery (BCS) in ductal carcinoma in situ (DCIS) have been shown to reduce the risk of local recurrence. To predict the risk of ipsilateral breast tumor relapse (IBTR) after BCS, the Memorial Sloan Kettering Cancer Center (MSKCC) developed a nomogram to analyze local recurrence (LR) risk in our cohort and to assess its external validation. Methods: A historical cohort study using data from 296 patients treated for DCIS at the Hospital Clínic of Barcelona was carried out. Patients who had had a mastectomy were excluded from the analysis. Results: The mean age was 58 years (42–75), and the median follow-up time was 10.64 years. The overall local relapse rate was 13.04% (27 patients) during the study period. Actuarial 5- and 10-year IBTR rates were 5.8 and 12.9%, respectively. The external validation of the MSKCC nomogram was performed using a multivariate logistic regression analysis on a total of 207 patients, which did not reach statistical significance in the studied population for predicting LR (p = 0.10). The expression of estrogen receptors was significantly associated with a decreased risk of LR (OR: 0.25; p = 0.004). Conclusions: In our series, the LR rate was 13.4%, which was in accordance with the published series. The MSKCC nomogram did not accurately predict the IBTR in this Spanish cohort of patients treated for DCIS (p = 0.10).
format Online
Article
Text
id pubmed-10136555
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101365552023-04-28 Analysis of Local Recurrence Risk in Ductal Carcinoma In Situ and External Validation of the Memorial Sloan Kettering Cancer Center Nomogram Oses, Gabriela Mension, Eduard Pumarola, Claudia Castillo, Helena Francesc, León Torras, Inés Cebrecos, Isaac Caparrós, Xavier Ganau, Sergi Ubeda, Belén Bargallo, Xavier González, Blanca Sanfeliu, Esther Vidal-Sicart, Sergi Moreno, Reinaldo Muñoz, Montserrat Santamaría, Gorane Mollà, Meritxell Cancers (Basel) Article SIMPLE SUMMARY: Adjuvant treatments after breast-conserving surgery (BCS) in ductal carcinoma in situ (DCIS) have shown to reduce the risk of ipsilateral breast tumor relapse (IBTR), but its effect on overall survival remains controversial. Due to this argument, some nomograms tried to select the patients who may benefit the most to these not free of side-effects adjuvant treatments. In this study, an external validation of the Memorial Sloan Kettering Cancer Center (MSKCC) nomogram was performed not reaching statistical significance in a Spanish cohort of patients. Nonetheless, the expression of estrogen receptors, not included in the MSKCC nomogram, showed potential prediction power for IBTR in the studied population and may be considered in future nomograms. ABSTRACT: Background: Adjuvant radiotherapy and hormonotherapy after breast-conserving surgery (BCS) in ductal carcinoma in situ (DCIS) have been shown to reduce the risk of local recurrence. To predict the risk of ipsilateral breast tumor relapse (IBTR) after BCS, the Memorial Sloan Kettering Cancer Center (MSKCC) developed a nomogram to analyze local recurrence (LR) risk in our cohort and to assess its external validation. Methods: A historical cohort study using data from 296 patients treated for DCIS at the Hospital Clínic of Barcelona was carried out. Patients who had had a mastectomy were excluded from the analysis. Results: The mean age was 58 years (42–75), and the median follow-up time was 10.64 years. The overall local relapse rate was 13.04% (27 patients) during the study period. Actuarial 5- and 10-year IBTR rates were 5.8 and 12.9%, respectively. The external validation of the MSKCC nomogram was performed using a multivariate logistic regression analysis on a total of 207 patients, which did not reach statistical significance in the studied population for predicting LR (p = 0.10). The expression of estrogen receptors was significantly associated with a decreased risk of LR (OR: 0.25; p = 0.004). Conclusions: In our series, the LR rate was 13.4%, which was in accordance with the published series. The MSKCC nomogram did not accurately predict the IBTR in this Spanish cohort of patients treated for DCIS (p = 0.10). MDPI 2023-04-21 /pmc/articles/PMC10136555/ /pubmed/37190320 http://dx.doi.org/10.3390/cancers15082392 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Oses, Gabriela
Mension, Eduard
Pumarola, Claudia
Castillo, Helena
Francesc, León
Torras, Inés
Cebrecos, Isaac
Caparrós, Xavier
Ganau, Sergi
Ubeda, Belén
Bargallo, Xavier
González, Blanca
Sanfeliu, Esther
Vidal-Sicart, Sergi
Moreno, Reinaldo
Muñoz, Montserrat
Santamaría, Gorane
Mollà, Meritxell
Analysis of Local Recurrence Risk in Ductal Carcinoma In Situ and External Validation of the Memorial Sloan Kettering Cancer Center Nomogram
title Analysis of Local Recurrence Risk in Ductal Carcinoma In Situ and External Validation of the Memorial Sloan Kettering Cancer Center Nomogram
title_full Analysis of Local Recurrence Risk in Ductal Carcinoma In Situ and External Validation of the Memorial Sloan Kettering Cancer Center Nomogram
title_fullStr Analysis of Local Recurrence Risk in Ductal Carcinoma In Situ and External Validation of the Memorial Sloan Kettering Cancer Center Nomogram
title_full_unstemmed Analysis of Local Recurrence Risk in Ductal Carcinoma In Situ and External Validation of the Memorial Sloan Kettering Cancer Center Nomogram
title_short Analysis of Local Recurrence Risk in Ductal Carcinoma In Situ and External Validation of the Memorial Sloan Kettering Cancer Center Nomogram
title_sort analysis of local recurrence risk in ductal carcinoma in situ and external validation of the memorial sloan kettering cancer center nomogram
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136555/
https://www.ncbi.nlm.nih.gov/pubmed/37190320
http://dx.doi.org/10.3390/cancers15082392
work_keys_str_mv AT osesgabriela analysisoflocalrecurrenceriskinductalcarcinomainsituandexternalvalidationofthememorialsloanketteringcancercenternomogram
AT mensioneduard analysisoflocalrecurrenceriskinductalcarcinomainsituandexternalvalidationofthememorialsloanketteringcancercenternomogram
AT pumarolaclaudia analysisoflocalrecurrenceriskinductalcarcinomainsituandexternalvalidationofthememorialsloanketteringcancercenternomogram
AT castillohelena analysisoflocalrecurrenceriskinductalcarcinomainsituandexternalvalidationofthememorialsloanketteringcancercenternomogram
AT francescleon analysisoflocalrecurrenceriskinductalcarcinomainsituandexternalvalidationofthememorialsloanketteringcancercenternomogram
AT torrasines analysisoflocalrecurrenceriskinductalcarcinomainsituandexternalvalidationofthememorialsloanketteringcancercenternomogram
AT cebrecosisaac analysisoflocalrecurrenceriskinductalcarcinomainsituandexternalvalidationofthememorialsloanketteringcancercenternomogram
AT caparrosxavier analysisoflocalrecurrenceriskinductalcarcinomainsituandexternalvalidationofthememorialsloanketteringcancercenternomogram
AT ganausergi analysisoflocalrecurrenceriskinductalcarcinomainsituandexternalvalidationofthememorialsloanketteringcancercenternomogram
AT ubedabelen analysisoflocalrecurrenceriskinductalcarcinomainsituandexternalvalidationofthememorialsloanketteringcancercenternomogram
AT bargalloxavier analysisoflocalrecurrenceriskinductalcarcinomainsituandexternalvalidationofthememorialsloanketteringcancercenternomogram
AT gonzalezblanca analysisoflocalrecurrenceriskinductalcarcinomainsituandexternalvalidationofthememorialsloanketteringcancercenternomogram
AT sanfeliuesther analysisoflocalrecurrenceriskinductalcarcinomainsituandexternalvalidationofthememorialsloanketteringcancercenternomogram
AT vidalsicartsergi analysisoflocalrecurrenceriskinductalcarcinomainsituandexternalvalidationofthememorialsloanketteringcancercenternomogram
AT morenoreinaldo analysisoflocalrecurrenceriskinductalcarcinomainsituandexternalvalidationofthememorialsloanketteringcancercenternomogram
AT munozmontserrat analysisoflocalrecurrenceriskinductalcarcinomainsituandexternalvalidationofthememorialsloanketteringcancercenternomogram
AT santamariagorane analysisoflocalrecurrenceriskinductalcarcinomainsituandexternalvalidationofthememorialsloanketteringcancercenternomogram
AT mollameritxell analysisoflocalrecurrenceriskinductalcarcinomainsituandexternalvalidationofthememorialsloanketteringcancercenternomogram